Format

Send to

Choose Destination
Cancer Control. 2010 Oct;17(4):245-55.

Promoter hypermethylation in prostate cancer.

Author information

1
Division of Cancer Prevention and Control, Moffitt Cancer Center, Tampa, FL 33612, USA. Jong.Park@moffitt.org

Abstract

BACKGROUND:

The prostate gland is the most common site of cancer and the second leading cause of cancer mortality in American men. It is well known that epigenetic alterations such as DNA methylation within the regulatory (promoter) regions of genes are associated with transcriptional silencing in cancer. Promoter hypermethylation of critical pathway genes could be potential biomarkers and therapeutic targets for prostate cancer.

METHODS:

This review discusses current information on methylated genes associated with prostate cancer development and progression.

RESULTS:

Over 30 genes have been investigated for promoter methylation in prostate cancer. These methylated genes are involved in critical pathways, such as DNA repair, metabolism, and invasion/metastasis. The role of hypermethylated genes in regulation of critical pathways in prostate cancer is reviewed.

CONCLUSIONS:

These findings may provide new information of the pathogenesis of prostate cancer. Certain epigenetic alterations in prostate tumors are being translated into clinical practice for therapeutic use.

PMID:
20861812
PMCID:
PMC3167691
DOI:
10.1177/107327481001700405
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center